IBRANCE Home

IBRANCE is the first-in-class CDK4/6 inhibitor backed by two Phase 3 clinical trials and 4+ years in the market1,2
4+ years
since initial FDA approval
13,000+ prescribers
have chosen IBRANCE3*
100,000+ patients
prescribed IBRANCE3*
TWO CATEGORY 1 RECOMMENDATIONS FROM
THE NATIONAL COMPREHENSIVE CANCER NETWORK®4†‡
Palbociclib (IBRANCE) + aromatase inhibitor
May be considered as a treatment option for first-line therapy for women who are
Palbociclib (IBRANCE) + fulvestrant
postmenopausal or premenopausal (receiving ovarian suppression or ablation with an LHRH agonist) with HR+/HER2- MBC§
 
Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.4
Aromatase inhibitors and fulvestrant have category 1 recommendations in combination with any CDK4/6 inhibitor.4
§If there is disease progression while on CDK4/6 inhibitor therapy, there are no data to support an additional line of therapy with another CDK4/6-containing regimen.4
*Estimated data, as of February 2019.3
CDK4/6=cyclin-dependent kinases 4 and 6; LHRH=luteinizing hormone-releasing hormone; MBC=metastatic breast cancer; NCCN®=National Comprehensive Cancer Network®.
The NCCN Guidelines® above fall outside the palbociclib (IBRANCE)
US Prescribing Information.
IBRANCE Indications
IBRANCE is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) in combination with:
  • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
  • fulvestrant in patients with disease progression following endocrine therapy
The appropriate use of IBRANCE should be based on a risk/benefit assessment by the practitioner for an individual patient.
REFERENCES
1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936.
2. Turner NC, Ro J, André F, et al; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209-219.
3. Data on file. Pfizer Inc, New York, NY.
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed March 14, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.